Topic Review
Non-invasive diagnosis of mucosal melanoma
Mucosal melanoma is a rare tumor with aggressive biological behavior and poor prognosis. Diagnosis is often performed at an advanced stage when the lesions become symptomatic. Although dermoscopy and reflectance confocal microscopy (RCM) are widely used techniques for the diagnosis of cutaneous tumors, their use for mucosal lesions is not well established, probably because the latter are rarer.
  • 613
  • 23 Feb 2021
Topic Review
Melanogenesis and Melasma Treatment
Melanin is a complex pigment that provides colour and photoprotection to the skin, hair, and eyes of mammals. Melanogenesis, the process through which melanocytes synthesise melanin, can be altered, producing pigmentary skin disorders such as melasma which result in hyperpigmentation. Melanocytes are highly specialised dendritic cells that transfer melanin to keratinocytes in subcellular lysosome-like organelles called melanosomes, where melanin is synthesised and stored.
  • 599
  • 08 Sep 2021
Topic Review
RAGE and Oxidative Stress
The surface receptor for advanced glycosylation end-products (RAGE) and its soluble (sRAGE) and endogenous secretory (EN-RAGE) forms belong to the superfamily of toll-like receptors and play important roles in inflammation and autoimmunity, directly or through binding with advanced glycosylation end-products (AGE) and advanced oxidation protein products (AOPP).
  • 598
  • 08 Mar 2021
Topic Review
Cutaneous Immune-Related Adverse Events
Dermatologic complications arise as the earliest and most frequently observed adverse events among all immune-related adverse events (irAEs), affecting between 30 and 50% of patients on Immune checkpoint inhibitors (ICIs). The symptoms may significantly impair patients’ quality of life, and even lead to a pause of immunotherapy treatment. Fortunately, the majority of cirAEs seem to be mild and manageable, but there are still a few serious events (grade III or IV) being observed. Maculopapular rash, pruritus, lichenoid eruptions, and vitiligo are the most widely reported cutaneous adverse events. Severe cutaneous adverse reactions (SCARs), consisting of Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug rash with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), are rare but potentially life-threatening. Other less-frequent manifestations include ICI-induced dermatomyositis, Sweet syndrome, interstitial granulomatous dermatitis, pityriasis rubra pilaris-like erythroderma, and lupus-like cutaneous reaction.
  • 595
  • 28 Apr 2022
Topic Review
Mechanisms and Classification of Bioactive Peptides
Bioactive peptides have gained significant attention in the cosmetic industry due to their potential in enhancing skin health and beauty. These small protein fragments exhibit various biological activities, such as antioxidant, anti-aging, anti-inflammatory, and antimicrobial activities, making them ideal ingredients for cosmetic formulations. These bioactive peptides are classified into four categories: signal, carrier, neurotransmitter-inhibitory, and enzyme-inhibitory peptides. 
  • 593
  • 18 Aug 2023
Topic Review
Caspase Inhibition in Pemphigus Vulgaris Treatment
Pemphigus vulgaris is a potentially fatal autoimmune blistering disease characterised by blister formation affecting the skin and mucous membranes.
  • 590
  • 23 Mar 2022
Topic Review
Stem Cells-Derived Extracellular Vesicles
Endosome-derived small extracellular vesicles (EVs), often referred to as exosomes, are produced by almost all, if not all, cell types, and are critical for intercellular communication. They are composed of a lipid bilayer associated with membrane proteins and contain a payload of lipids, proteins and regulatory RNAs that depends on the parental cell physiological condition. By transferring their “cargo”, exosomes can modulate the phenotype of neighboring and distant cells. Stem cells (SC) were widely studied for therapeutic applications regarding their regenerative/reparative potential as well as their immunomodulatory properties. Whether from autologous or allogeneic source, SC beneficial effects in terms of repair and regeneration are largely attributed to their paracrine signaling notably through secreted EVs. Subsequently, SC-derived EVs have been investigated for the treatment of various diseases, including inflammatory skin disorders, and are today fast-track cell-free tools for regenerative/reparative strategies. 
  • 588
  • 22 Sep 2021
Topic Review
The interleukin-1 Family Cytokines, Receptors and Co-Receptors
The interleukin-1 (IL-1) family is involved in the correct functioning and regulation of the innate immune system, linking innate and adaptative immune responses. This complex family is composed by several cytokines, receptors, and co-receptors, all working in a balanced way to maintain homeostasis. 
  • 584
  • 06 Sep 2022
Topic Review
Treatment of Vulvar Lichen Sclerosus
Vulvar lichen sclerosus (VLS) is a chronic inflammatory disease involving the genital skin and mucous membrane. 
  • 579
  • 04 Jan 2022
Topic Review
Biomarkers in Atopic Dermatitis
Atopic dermatitis (AD) is a highly heterogeneous inflammatory disease regarding both its pathophysiology and clinical manifestations. However, it is treated according to the “one-size-fits-all” approach, which may restrict response to treatment. Thus, there is an unmet need for the stratification of patients with AD into distinct endotypes and clinical phenotypes based on biomarkers that will contribute to the development of precision medicine in AD. The development of reliable biomarkers that may distinguish which patients with AD are most likely to benefit from specific targeted therapies is a complex procedure and to date none of the identified candidate biomarkers for AD has been validated for use in routine clinical practice. Reliable biomarkers in AD are expected to improve diagnosis, evaluate disease severity, predict the course of disease, the development of comorbidities, or the therapeutic response, resulting in effective and personalized treatment of AD. 
  • 576
  • 25 Aug 2022
  • Page
  • of
  • 34
ScholarVision Creations